Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2000 | 12-1999 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 33,129 | 15,010 |
| Receivables | 45,949 | 36,290 |
| Inventories | 34,510 | 30,530 |
| Income taxes - deferred | 2,055 | N/A |
| Other current assets | 4,094 | 8,240 |
| TOTAL | $119,737 | $90,070 |
| Non-Current Assets | ||
| PPE Net | 117,001 | 85,410 |
| Investments And Advances | 2,442 | 21,720 |
| Intangibles | 41,893 | 0 |
| Other Non-Current Assets | 132,472 | 165,830 |
| TOTAL | $293,808 | $272,960 |
| Total Assets | $413,545 | $363,050 |
| Liabilities | ||
| Current Liabilities | ||
| Short Term Debt | 231 | 3,290 |
| Accounts payable and accrued liabilities | 10,767 | 9,290 |
| Accrued Expenses | 44,635 | 46,520 |
| Other current liabilities | N/A | 7,640 |
| TOTAL | $64,320 | $69,730 |
| Non-Current Liabilities | ||
| Long Term Debt | 201,957 | 381,700 |
| Deferred Revenues | 5,223 | N/A |
| Other Non-Current Liabilities | 16,745 | 15,960 |
| TOTAL | $229,361 | $403,440 |
| Total Liabilities | $293,681 | $473,190 |
| Shareholders' Equity | ||
| Common Shares | 359 | 100 |
| Retained earnings | -318,575 | -307,350 |
| Other shareholders' equity | -13,324 | -9,920 |
| TOTAL | $119,864 | $-110,140 |
| Total Liabilities And Equity | $413,545 | $363,050 |